Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

Frankloka Dec. 23 at 1:40 AM

$JNJ 300$$$

0 · Reply

MoneyGroupLLC Dec. 22 at 11:20 PM

Enter: $JNJ Calls Strike Price: $210 Expiry Date: JAN 16 2026 Buy in Price: $2.65 - $2.97 Sell Price: $5.43 Profit : +105% (Turn every $1 into $2.05) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Diefreeandsell Dec. 22 at 9:40 PM

$CAPR Boring myself saying this again but BO is coming! This co represents a Significant Market Opportunity for the likes of $AZ $MRK $PFE $JNJ There is currently no competition for the cardiomyopathy label in DMD, representing a large commercial opportunity. A potential acquirer would be interested in this untapped market. The average price target from analysts ranges from approximately $40 to over $50 per share, with some high-end forecasts reaching $60 or more. The stock consistently holding above the recent offering price of $25 per share is a technical indicator of strong institutional interest and support, reinforcing the bullish outlook of a BO!

1 · Reply

ZacksResearch Dec. 22 at 5:52 PM

$JNJ showing real strength — 6 months above both the 50- & 200-day SMAs 👀 The stock has held key technical levels for half a year as strong 2025 execution, new drugs, and pipeline progress continue to support bullish momentum. That’s a combo trend-followers don’t ignore. How to play J&J from here? Full breakdown 👉 https://www.zacks.com/stock/news/2807494/jj-stock-trading-above-50--200-day-sma-for-6-months-how-to-play?cid=sm-stocktwits-2-2807494-teaser-25860&ADID=SYND_STOCKTWITS_TWEET_2_2807494_TEASER_25860

0 · Reply

illiquid Dec. 22 at 4:56 PM

$JNJ At 17x, it’s priced for infinite U.S. pricing power. China can ban its medical devices (already started). Not defensive.

1 · Reply

ZacksResearch Dec. 22 at 4:52 PM

$JNJ ’s resilience: Outperforming industry, sector & S&P 500! 🚀 📈 Stock up 42.1% in the past year, beating a 15.2% industry rise. 💊 Strong Innovative Medicine growth despite Stelara’s LOE. 🔬 New launches expected to fuel future momentum. Is JNJ a buy despite headwinds? Full analysis here 👉 https://www.zacks.com/stock/news/2807494/jj-stock-trading-above-50--200-day-sma-for-6-months-how-to-play?cid=sm-stocktwits-2-2807494-body-25857&ADID=SYND_STOCKTWITS_TWEET_2_2807494_BODY_25857

0 · Reply

th66 Dec. 22 at 4:20 PM

$JNJ Can't keep it down much longer

0 · Reply

Wallstfan Dec. 22 at 3:35 PM

$JNJ added at $205.60. Looking for $275 by end of 2026

0 · Reply

KingdomTrading Dec. 22 at 12:14 PM

$JNJ 📈 Moderate Outlook Price: $206.37 Entry: $206.37 Target: $213.67 Expected Move: +3.54% Timeframe: 12 The content provided on https://stocksurger.com/ is for informational purposes only and does not constitute a recommendation to buy or sell any security.

0 · Reply

RoadWarrior66 Dec. 22 at 4:47 AM

$JNJ ..Woody…SELL THE JETS ALREADY…you are the undisputed worst owner in the NFL..period!!

0 · Reply

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

Dec 19, 2025, 5:54 PM EST - 3 days ago

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Dec 18, 2025, 8:00 AM EST - 4 days ago

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Dec 18, 2025, 2:09 AM EST - 4 days ago

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Dec 17, 2025, 6:49 PM EST - 5 days ago

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

Dec 15, 2025, 6:22 PM EST - 7 days ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER

Dec 15, 2025, 4:27 PM EST - 7 days ago

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Dec 15, 2025, 10:39 AM EST - 7 days ago

US FDA grants priority voucher to J&J's blood cancer treatment

Dec 14, 2025, 9:00 AM EST - 8 days ago

California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson

Dec 12, 2025, 9:08 PM EST - 10 days ago

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial

Dec 12, 2025, 8:25 PM EST - 10 days ago

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

Dec 11, 2025, 7:05 PM EST - 11 days ago

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 9, 2025, 9:50 PM EST - 12 days ago

GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities

ACN DHI HON KVUE ORCL SSB WFC

Dec 9, 2025, 12:18 PM EST - 13 days ago

5 defensive stocks traders are buying before the Fed rate-cut decision

DUK KO NEE PG

$Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma$

Dec 9, 2025, 7:44 AM EST - 13 days ago

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

Dec 8, 2025, 4:25 PM EST - 14 days ago

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

$Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma$

Dec 6, 2025, 9:30 AM EST - 16 days ago

Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

Dec 5, 2025, 4:20 PM EST - 17 days ago

Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC

Dec 3, 2025, 2:13 PM EST - 19 days ago

Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 1, 2025, 1:36 PM EST - 21 days ago

American Century Value Fund Q3 2025 Contributors/Detractors And Notable Trades

BWA CNC CRM KVUE LMT NVT TER

Dec 1, 2025, 1:23 PM EST - 21 days ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM

Dec 1, 2025, 8:18 AM EST - 21 days ago

Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)

Nov 29, 2025, 8:02 AM EST - 23 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR

Nov 29, 2025, 1:45 AM EST - 23 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY

Nov 28, 2025, 7:50 AM EST - 24 days ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA

Nov 25, 2025, 5:20 AM EST - 27 days ago

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

PFE

Nov 18, 2025, 4:21 PM EST - 4 weeks ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN LLY MDT MRK NVO OLMA PFE

Nov 18, 2025, 8:25 AM EST - 4 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK LLY

Nov 17, 2025, 6:07 PM EST - 5 weeks ago

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Nov 17, 2025, 1:17 PM EST - 5 weeks ago

Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 8:29 AM EST - 5 weeks ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:15 AM EST - 5 weeks ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:07 AM EST - 5 weeks ago

J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion

Nov 17, 2025, 8:05 AM EST - 5 weeks ago

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Nov 17, 2025, 8:00 AM EST - 5 weeks ago

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Nov 14, 2025, 3:19 PM EST - 5 weeks ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV AZN LLY MRK NVO PFE XLV

Nov 14, 2025, 8:03 AM EST - 5 weeks ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY

Nov 11, 2025, 1:41 PM EST - 5 weeks ago

Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 12:51 PM EST - 5 weeks ago

Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 10, 2025, 6:26 AM EST - 6 weeks ago

Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating

Nov 7, 2025, 12:57 PM EST - 6 weeks ago

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

Nov 7, 2025, 5:40 AM EST - 6 weeks ago

Johnson & Johnson: Dividends Don't Lie

Nov 6, 2025, 5:07 PM EST - 6 weeks ago

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Nov 6, 2025, 9:54 AM EST - 6 weeks ago

Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 7:34 AM EST - 6 weeks ago

US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:30 AM EST - 6 weeks ago

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Nov 5, 2025, 4:50 PM EST - 6 weeks ago

Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference

Nov 1, 2025, 10:25 AM EDT - 7 weeks ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO

Oct 29, 2025, 8:05 AM EDT - 7 weeks ago

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Oct 29, 2025, 5:11 AM EDT - 7 weeks ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BDX

Frankloka Dec. 23 at 1:40 AM

$JNJ 300$$$

0 · Reply

MoneyGroupLLC Dec. 22 at 11:20 PM

0 · Reply

Diefreeandsell Dec. 22 at 9:40 PM

1 · Reply

ZacksResearch Dec. 22 at 5:52 PM

0 · Reply

illiquid Dec. 22 at 4:56 PM

$JNJ At 17x, it’s priced for infinite U.S. pricing power. China can ban its medical devices (already started). Not defensive.

1 · Reply

ZacksResearch Dec. 22 at 4:52 PM

0 · Reply

th66 Dec. 22 at 4:20 PM

$JNJ Can't keep it down much longer

0 · Reply

Wallstfan Dec. 22 at 3:35 PM

$JNJ added at $205.60. Looking for $275 by end of 2026

0 · Reply

KingdomTrading Dec. 22 at 12:14 PM

0 · Reply

RoadWarrior66 Dec. 22 at 4:47 AM

$JNJ ..Woody…SELL THE JETS ALREADY…you are the undisputed worst owner in the NFL..period!!

0 · Reply

1iquid Dec. 21 at 7:40 PM

💎 Liquid® Live Actionable Trade Asset: $JNJ Contracts: $JNJ January 15, 2027 $210 Calls Scale in: $15.14- $18.51 Scale out: $58.89-$100.95 Profit Potential : 292% ROI Blended Join 💎 Here: https://1iquid.com

0 · Reply

EthelBurkhardt272 Dec. 21 at 3:19 PM

$JNJ Boring on purpose, steady compounder doing its job

0 · Reply

MoneyGroupLLC Dec. 20 at 10:31 PM

Enter: $JNJ Calls Strike Price: $210 Expiry Date: JAN 09 2026 Buy in Price: $2.87 - $2.93 Sell Price: $6.56 Profit : +124% (Turn every $1 into $2.24) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

MetalinMaybach Dec. 20 at 7:21 PM

$JNJ NGENF is getting ready to list with Nasdaq very soon. This is mainly focused in the SCI space but has applications in other CNS diseases as shown in preclinical trials. If it lists this will be a good opportunity to capitalize on benefits of more exposure.

0 · Reply

Suite510 Dec. 20 at 12:23 PM

$JNJ $KVUE $SPX The boat is sinking again 😂 Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder Minnesota jury has awarded $65.5 million to a woman who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing mesothelioma ByThe Associated Press December 19, 2025, 8:38 PM

0 · Reply

1iquid Dec. 20 at 5:50 AM

OptionWizards Tip (education only): Before trading options on MA, NFLX, or JNJ, review the company’s upcoming earnings dates to avoid unexpected volatility. $MA $NFLX $JNJ Not financial advice.

0 · Reply

clan Dec. 20 at 12:24 AM

$MNKD All analysts' PTs for MNKD are much much higher than today's close. Do you see this, $JNJ $MRK $SNY ?

0 · Reply

3DBuilds Dec. 19 at 11:27 PM

$CRBU $NTLA $EDIT $JNJ $BMY Amazing 🤩 Jennifer and Zuckerberg next year 💯 things are gunna get Amazing 🌎

0 · Reply

dudebob Dec. 19 at 10:32 PM

Attn. pharma & battery/ev folks ‼️ Something is goin on with $KODK .. major end of day volume! # $JNJ $TSLA $TEVA $ABAT

0 · Reply

PickAlpha Dec. 19 at 8:40 PM

PickAlpha Mid-Day — Trump locks in pharma price pacts President Trump said the White House reached pricing deals with nine drugmakers, taking the total to 14 of 17 targeted this summer. The agreements aim to cut prices for Medicaid, push direct-to-consumer discounted sales (via a planned TrumpRX site), and tie some new US launch prices closer to overseas levels — in exchange for a 3-year reprieve from threatened tariffs. Names cited include NVS / BMY / GILD / AMGN / GSK / SNY / MRK; holdouts: ABBV / JNJ / REGN. Our view is: this is policy-driven margin risk packaged as “tariff relief.” The market will reprice on how enforceable the confidential terms are and whether “MFN-style” pricing spreads beyond Medicaid/DTC into broader commercial channels. Near-term, the uncertainty premium rises for the remaining holdouts (they’re next in line), while “deal signers” get headline relief but face a multiple cap until the revenue/mix impact is quantified. Tickers $MRK $ABBV $JNJ

0 · Reply

SimpleWinningSetups Dec. 19 at 8:24 PM

Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $207.50 Put · DEC 26, 2025 Exp Entry Price: $1.50 - $1.58 Exit Price Target: $3.53 Profit Margin: +135% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

th66 Dec. 19 at 7:21 PM

$JNJ President Trump just mentioned jnj will have meeting next week

0 · Reply

Market Cap	497.21B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	19.88
Forward PE	18.99
Profit Margin	15.84%
Debt to Equity Ratio	0.50

Volume	8,187,700
Avg Vol	9,122,028
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	42%
Beta	0.36
Analysts	Strong Sell
Price Target	$211.12